Modeling chemotherapy-induced stress to identify rational combination therapies in the DNA damage response pathway
Cells respond to DNA damage by activating complex signaling networks that decide cell fate, promoting not only DNA damage repair and survival but also cell death. We have developed a multiscale computational model that quantitatively links chemotherapy-induced DNA damage response signaling to cell fate. The computational model was trained and calibrated on extensive data from U2OS osteosarcoma cells, including the cell cycle distribution of the initial cell population, signaling data measured by Western blotting, and cell fate data in response to chemotherapy treatment measured by time-lapse microscopy. The resulting mecha...
Source: Signal Transduction Knowledge Environment - July 24, 2018 Category: Science Authors: Alkan, O., Schoeberl, B., Shah, M., Koshkaryev, A., Heinemann, T., Drummond, D. C., Yaffe, M. B., Raue, A. Tags: STKE Research Articles Source Type: news
Medical News Today: What is osteosarcoma?
Osteosarcoma is a type of bone cancer that often affects the shinbone, thighbone, or upper arm. Doctors are currently unsure of the causes, but genetics may play a role. Treatment includes chemotherapy and surgery. The outlook depends on if and how far cancerous cells have spread. Learn more about osteosarcoma here. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - July 23, 2018 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news
Emma Neagu had her foot fitted backwards after having bone cancer
Emma Neagu, now 14, from Toronto, was diagnosed with a form of bone cancer known as osteosarcoma in 2016. The teen endured nine months of grueling chemotherapy. (Source: the Mail online | Health)
Source: the Mail online | Health - July 23, 2018 Category: Consumer Health News Source Type: news
Gymnast, 14, chose to have her foot removed and refitted backwards after developing bone cancer
Emma Neagu, now 14, from Toronto, was diagnosed with a form of bone cancer known as osteosarcoma in 2016. The teen endured nine months of grueling chemotherapy. (Source: the Mail online | Health)
Source: the Mail online | Health - July 23, 2018 Category: Consumer Health News Source Type: news
Products of omega-3 fatty acid metabolism may have anticancer effects, study shows
(University of Illinois at Urbana-Champaign) A class of molecules formed when the body metabolizes omega-3 fatty acids could inhibit cancer's growth and spread, University of Illinois researchers report in a new study in mice. In mice with tumors of osteosarcoma - a bone cancer that is notoriously painful and difficult to treat -- endocannabinoids slowed the growth of tumors and blood vessels, inhibited the cancer cells from migrating and caused cancer cell death. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 13, 2018 Category: International Medicine & Public Health Source Type: news
Olathe biotech moves dog cancer treatment closer to market
A Kansas City-area animal health company is ramping up its efforts to take its cancer immunotherapy treatment to market.
Elias Animal Health, a subsidiary of Olathe-based TVAX Biomedical Inc., applied for a conditional licensure of its treatment for dogs with bone cancer through the U.S. Department of Agriculture’s Center for Veterinary Biologics.
Elias recently completed preliminary studies of its osteosarcoma treatment and will enroll for a pivotal study as the next step. On Thursday, the… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - June 14, 2018 Category: American Health Authors: Elise Reuter Source Type: news
Genetic discovery will help clinicians identify aggressive versus benign bone tumors
(Wellcome Trust Sanger Institute) The first genetic marker for the bone tumor, osteoblastoma, has been discovered by scientists at the Wellcome Sanger Institute and their collaborators. Whole-genome and transcriptome sequencing of human bone tumors revealed that a genetic change that affects the transcription factor, FOS, is a hallmark mutation of osteoblastoma. The results, published in Nature Communications, will help clinicians correctly distinguish benign osteoblastoma tumors from aggressive osteosarcoma tumors and direct the correct treatment. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 12, 2018 Category: Cancer & Oncology Source Type: news
Innovative vaccine offers canine cancer patients a shot at a longer, happier life
(University of Pennsylvania) Nicola Mason of the School of Veterinary Medicine is leading a multi-institutional clinical trial evaluating an immunotherapy approach to treat dogs with osteosarcoma, a cancer of the bone. A new $775,000 grant from the Morris Animal Foundation will help her build on her past successes. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 1, 2018 Category: Cancer & Oncology Source Type: news
Morris Animal Foundation awards $775K to test osteosarcoma immunotherapy vaccine in dogs
(Morris Animal Foundation) Morris Animal Foundation has awarded a $775,000 grant to the University of Pennsylvania to test a vaccine that could improve longevity and quality of life for dogs with the deadly bone tumor, osteosarcoma. The research team will conduct clinical trials to evaluate a novel immunotherapy treatment which combines a molecule expressed by cancer cells with a modified live form of the bacteria Listeria monocytogenes. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - April 17, 2018 Category: Biology Source Type: news
PET imaging could help personalize cancer treatment
Researchers have developed a same-day, noninvasive PET imaging approach to...Read more on AuntMinnie.comRelated Reading:
FDG-PET/CT predicts outcomes in pediatric osteosarcoma
Artificial intelligence guides lower PET tracer dose
PET tracer could better assess lung ailments
SNMMI posts criteria for somatostatin receptor PET
Deep learning analyzes PET for signs of dementia (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - March 2, 2018 Category: Radiology Source Type: news
Gemcitabine Plus Sirolimus for Osteosarcoma Gemcitabine Plus Sirolimus for Osteosarcoma
The combination of gemcitabine and sirolimus may be a safe and effective option for patients with relapsed unresectable osteosarcoma.Annals of Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 23, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
Alex Huang, M.D., Ph.D., receives $450,000 from Pediatric Cancer Research Foundation
(Case Western Reserve University) Leading cancer researcher, Alex Huang M.D., Ph.D., has received a $450,000 Basic Science grant from Pediatric Cancer Research Foundation to study targeted approaches for effectively eliminating metastatic osteosarcoma. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 25, 2018 Category: International Medicine & Public Health Source Type: news
FDG-PET/CT predicts outcomes in pediatric osteosarcoma
The best way to predict a good outcome for pediatric patients with osteosarcoma...Read more on AuntMinnie.comRelated Reading:
UC Davis group reports progress on total-body PET/CT
FDA issues guidance on lowering pediatric x-ray dose
FDG-PET, DWI-MRI help predict osteosarcoma chemo response
FDG-PET/CT a good option for imaging pediatric osteosarcoma (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - January 19, 2018 Category: Radiology Source Type: news
Molecular imaging technique identifies lung nodules for resection in osteosarcoma patient
(SPIE--International Society for Optics and Photonics) Utility of near-infrared molecular imaging in a patient undergoing pulmonary metastasectomy for osteosarcoma has been reported by researchers from Perelman School of Medicine at the University of Pennsylvania and Purdue University. The work is reported in an article in the Journal of Biomedical Optics published this week by SPIE, the international society for optics and photonics. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 5, 2018 Category: International Medicine & Public Health Source Type: news
HKBU Chinese medicine scholars develop HKBU Chinese medicine scholars develop
(Hong Kong Baptist University) Chinese Medicine scholars at Hong Kong Baptist University (HKBU) have succeeded in developing a novel targeted delivery system for CRISPR/Cas9 to achieve therapeutic genome editing of VEGFA in osteosarcoma (OS). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 10, 2017 Category: International Medicine & Public Health Source Type: news
